Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 80
SponsorTongji Hospital
About this trial
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.
From March 1, 2021 to December 31, 2026, 1000 patients with ischemic stroke due to large-artery atherosclerosis who are admitted to the Department of Neurology or Neurosurgery, Tongji Hospital are going to be recruited. Detailed clinical data in emergency room and in-hospital will be obtained from the medical record reviews, and the National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) score will be done by certified neurologists to assess the severity of the disease in acute stage and treatment outcome during the follow-up. All cases will undergo routine blood tests, brain magnetic resonance imaging (MRI) and cerebral vascular examination, such as TCD, CTA, HRMR or DSA. The investigators will analyze the in-hospital factors that could predict the outcome to provide more evidence-based suggestions in the treatment and prognosis of atherosclerotic ischemic cerebrovascular disease.
Eligibility criteria
Qualifiers
Ischemic stroke due to large-artery atherosclerosis has been proved by clinical symptoms and imaging examinations.
Symptomatic superior arch stenosis >50%
Asymptomatic superior arch stenosis was >70%
written informed consent was obtained from patients or their surrogates before enrollment.
Disqualifiers
Brain CT or MRI showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation)
With severe systemic disease, are expected to survive < 3 months
Patients will not able to provide continuous follow-up information
Trial design
Treatments tested in this trial
- carotid artery stenting
- carotid endarterectomy
- Aspirin
- Clopidogrel
- Anticoagulant
- Statin
- PCSK9 inhibitor
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov